^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FGFR4 overexpression

i
Other names: FGFR4, CD334, JTK2, Fibroblast growth factor receptor 4
Entrez ID:
Related biomarkers:
11ms
FGFR3 and FGFR4 overexpression in juvenile nasopharyngeal angiofibroma: impact of smoking history and implications for personalized management. (PubMed, J Appl Genet)
Furthermore, medical reports indicated higher rates of recurrence and bleeding intensity among smokers. These findings emphasize the potential role of FGFR3 as a key molecular factor in JNA, particularly in the context of smoking.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR4 (Fibroblast growth factor receptor 4)
|
FGFR3 overexpression • FGFR overexpression • FGFR4 overexpression • FGFR3 expression • FGF3 overexpression
1year
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma. (PubMed, Cancers (Basel))
Moreover, we provide evidence that the combination of futibatinib with currently used chemotherapies such as irinotecan and vincristine has a synergistic effect against RMS in vitro. Moreover, limited efficacy is only observed in a PAX3-FOXO1 fusion-negative (FN) RMS cell line with mutationally activated FGFR4, whereas little or no efficacy is observed in PAX3-FOXO1 fusion-positive (FP) RMS cell lines with FGFR4 overexpression. Alternative treatment modalities such as combining futibatinib with other kinase inhibitors or targeting FGFR4 with CAR T cells or antibody-drug conjugate may be more effective than the approaches tested in this study.
Preclinical • Journal
|
FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • PAX3 (Paired Box 3)
|
FGFR4 overexpression • PAX3-FOXO1 fusion
|
Lytgobi (futibatinib) • irinotecan • vincristine
over1year
Inhibition of FGFR4 with futibatinib combined with inhibition of IGF1R, Src family kinases, or AKT is synergistic against rhabdomyosarcoma (AACR 2023)
The IC50 of futibatinib was ~500 nM for RMS559 and ~10 μM for RH4. Western blot showed that futibatinib inhibited FGFR4 phosphorylation in a dose dependent manner. The kinome activity assay found that futibatinib treatment resulted in SFK, AKT, and IGF1R activation.
Late-breaking abstract
|
FGFR4 (Fibroblast growth factor receptor 4) • PAX3 (Paired Box 3)
|
FGFR4 mutation • FGFR4 overexpression • PAX3-FOXO1 fusion
|
Lytgobi (futibatinib)
almost2years
Multiomics Profiling Characterizes Distinct HER2-low Breast Cancer Subgroups in the East Asian Population (SABCS 2022)
We reported the largest single-center multiomics HER2-low BC cohort in East Asian hitherto, and revealed its molecular nature, internal heterogeneity and ethnic difference. Compared with HR- positive diseases, HER2-low BCs in the HR-negative subgroup were more likely to be a molecularly distinct entity from HER2-0 tumors. Furthermore, HR-negative HER2-low BC also accommodates higher internal heterogeneity, which was ethnicity-specific in our East Asian cohort and may infer a different treatment response.
Clinical • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • AR (Androgen receptor) • NF1 (Neurofibromin 1) • FGFR4 (Fibroblast growth factor receptor 4) • PTK6 (Protein Tyrosine Kinase 6)
|
HER-2 positive • HR positive • HER-2 negative • PIK3CA mutation • HER-2 expression • FGFR4 overexpression • PIK3CA expression • PIK3CA overexpression
2years
Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer. (PubMed, Front Oncol)
When combined with an FGFR4 inhibitor, the anti-tumor effect of anti-PD-1 treatment increased significantly in a GC xenograft mouse model with overexpressed FGFR4. FGFRs has critical function in GC and associated with immune cell infiltration, which might be a potential prognosis biomarker and predictor of response to immunotherapy in GC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • CD8 (cluster of differentiation 8) • FGFR4 (Fibroblast growth factor receptor 4) • CD4 (CD4 Molecule)
|
FGFR1 expression • FGFR4 overexpression • FGFR4 expression
over2years
Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness. (PubMed, Acta Neuropathol Commun)
Accordingly, FGFR4 blockade profoundly sensitized FGFR4-overexpressing GBM models towards integrin/focal adhesion kinase inhibitors. Collectively, FGFR4 overexpression contributes to the malignant phenotype of a highly aggressive GBM subgroup and is associated with integrin-related therapeutic vulnerabilities.
Journal
|
FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4)
|
FGFR4 overexpression • FGFR4 expression
3years
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. (PubMed, Breast Cancer Res)
This work highlights how patient-derived models of human breast cancer provide powerful platforms for therapeutic target identification and analysis of drug action, and also the potential of specific FGFRs, including FGFR4, as targets for precision treatment.
Clinical • Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4)
|
FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR4 overexpression • FGFR4 expression
|
fexagratinib (ABSK091) • BLU 9931
over3years
Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma. (PubMed, J Transl Med)
We found that Src is essential for the endosomal delivery of the FGFR4 signaling complex in HCC. Our findings provide a scientific rationale for repurposing Src inhibitors for the treatment of HCCs in which the FGFR4 pathway is activated.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
FGFR4 overexpression • FGF19 expression • FGFR4 expression • FGFR expression • FGFR4 amplification • FGF19 amplification
|
dasatinib • BLU 9931